Latest Conference Articles

May 11th 2023, 6:47pm

ESMO Breast Cancer Virtual Meeting

Treatment with trastuzumab deruxtecan resulted in lower exposure-adjusted incidence rates per patient-year of treatment-emergent adverse effects compared with treatment of physician’s choice in patients with HER2-low unresectable and/or metastatic breast cancer, according to safety analysis from the phase 3 DESTINY-Breast04 trial.

May 11th 2023, 6:18pm

ESMO Breast Cancer Virtual Meeting

Elacestrant maintained the quality of life for patients with metastatic breast cancer for at least 6 treatment cycles, according to patient reported outcomes.

May 2nd 2023, 6:22pm

American Urological Association Annual Meeting

Sohail Dhanji, MD, discusses the effect of preoperative hypertension on survival outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma, and the importance of hypertension control in this population.

May 2nd 2023, 6:19pm

American Urological Association Annual Meeting

Eric A. Singer, MD, discusses the use of systemic pembrolizumab monotherapy in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle invasive bladder cancer.

May 2nd 2023, 6:00pm

American Urological Association Annual Meeting

Findings from the phase 3 ZIRCON trial showed that imaging with 89Zr-DFO-girentuximab could improve the identification and risk stratification of patients with renal tumors.

May 2nd 2023, 5:00pm

American Urological Association Annual Meeting

Apalutamide plus androgen deprivation therapy with or without abiraterone acetate and prednisone improved prostate-specific antigen progression-free survival in patients with biochemically relapsed prostate cancer, according to long-term follow-up data from the phase 3 PRESTO trial.

May 1st 2023, 4:18pm

American Urological Association Annual Meeting

Sia Daneshmand MD, discusses preliminary results from the phase 2 SunRISe-1 trial (NCT04640623) in patients with non–muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guérin.

May 1st 2023, 4:15pm

American Urological Association Annual Meeting

Fred Saad, MD, FRCS, discusses prostate-specific antigen (PSA) response and time to PSA progression with the combination of abiraterone acetate and olaparib in patients with metastatic castration-resistant prostate cancer.

May 1st 2023, 1:40pm

American Urological Association Annual Meeting

Treatment with pembrolizumab monotherapy resulted in stable long-term disease-free survival rates in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer.

May 1st 2023, 1:24pm

American Urological Association Annual Meeting

Treatment with TAR-200 produced complete responses and was well tolerated in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer, according to preliminary data from the phase 2b SunRISe-1 trial.

May 1st 2023, 12:56pm

American Urological Association Annual Meeting

Nivolumab following radical surgery continued to display a benefit in disease-free survival in patients with muscle-invasive urothelial carcinoma and muscle-invasive bladder cancer.

April 30th 2023, 4:43pm

American Urological Association Annual Meeting

Treatment with sintilimab in combination with axitinib resulted in tumor shrinkage with tolerable adverse effects in patients with advanced fumarate hydratase–deficient renal cell carcinoma.

April 30th 2023, 1:57pm

American Urological Association Annual Meeting

Specific comorbidities were linked with complications following partial nephrectomy, compared with radical nephrectomy, in patients with T1b to T2 renal cell carcinoma.

April 30th 2023, 1:45pm

American Urological Association Annual Meeting

Hypertension was found to be an independent risk factor for worse survival outcomes in patients with upper tract urothelial cancer undergoing radical nephroureterectomy.

April 30th 2023, 1:12pm

American Urological Association Annual Meeting

A high body mass index was linked with improved overall survival in patients with renal cell carcinoma undergoing radical nephrectomy.

April 29th 2023, 9:13pm

American Urological Association Annual Meeting

Benjamin H. Lowentritt, MD, FACS, discusses prostate-specific antigen response and time to castration resistance in patients with metastatic castration-sensitive prostate cancer started on apalutamide, enzalutamide, or abiraterone acetate.

April 29th 2023, 8:10pm

American Urological Association Annual Meeting

Roger Li, MD, discusses phase 2 data with the combination of CG0070 and pembrolizumab in patients with non–muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guérin.

April 29th 2023, 7:31pm

American Urological Association Annual Meeting

Treatment with the androgen receptor inhibitor enzalutamide plus leuprolide led to a significant reduction in the risk of metastasis or death compared with placebo plus leuprolide in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.

April 29th 2023, 6:53pm

American Urological Association Annual Meeting

Patients with metastatic castration-sensitive prostate cancer treated with the androgen receptor–signaling inhibitor apalutamide achieved prostate-specific antigen responses that trended higher and rates of progression to castration resistance that trended lower than those receiving enzalutamide or abiraterone acetate/

April 29th 2023, 5:47pm

American Urological Association Annual Meeting

A post-hoc analysis of the phase 3 ARASENS trial demonstrated that the addition of darolutamide to androgen deprivation therapy and docetaxel produced deep and durable prostate-specific antigen responses in patients with metastatic hormone-sensitive prostate cancer.